Literature DB >> 32113653

Charting the Fragmented Landscape of Drug Synergy.

Christian T Meyer1, David J Wooten2, Carlos F Lopez3, Vito Quaranta4.   

Abstract

Even as the clinical impact of drug combinations continues to accelerate, no consensus on how to quantify drug synergy has emerged. Rather, surveying the landscape of drug synergy reveals the persistence of historical fissures regarding the appropriate domains of conflicting synergy models - fissures impacting all aspects of combination therapy discovery and deployment. Herein we chronicle the impact of these divisions on: (i) the design, interpretation, and reproducibility of high-throughput combination screens; (ii) the performance of algorithms to predict synergistic mixtures; and (iii) the search for higher-order synergistic interactions. Further progress in each of these subfields hinges on reaching a consensus regarding the long-standing rifts in the field.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bliss Independence; Loewe Additivity; drug synergy

Mesh:

Year:  2020        PMID: 32113653      PMCID: PMC7986484          DOI: 10.1016/j.tips.2020.01.011

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  68 in total

1.  Prediction of multidimensional drug dose responses based on measurements of drug pairs.

Authors:  Anat Zimmer; Itay Katzir; Erez Dekel; Avraham E Mayo; Uri Alon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

2.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

3.  Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.

Authors:  Federica Eduati; Victoria Doldàn-Martelli; Bertram Klinger; Thomas Cokelaer; Anja Sieber; Fiona Kogera; Mathurin Dorel; Mathew J Garnett; Nils Blüthgen; Julio Saez-Rodriguez
Journal:  Cancer Res       Date:  2017-04-05       Impact factor: 12.701

4.  BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.

Authors:  Koen Van der Borght; Annelies Tourny; Rytis Bagdziunas; Olivier Thas; Maxim Nazarov; Heather Turner; Bie Verbist; Hugo Ceulemans
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

5.  COMBImage2: a parallel computational framework for higher-order drug combination analysis that includes automated plate design, matched filter based object counting and temporal data mining.

Authors:  Efthymia Chantzi; Malin Jarvius; Mia Niklasson; Anna Segerman; Mats G Gustafsson
Journal:  BMC Bioinformatics       Date:  2019-06-04       Impact factor: 3.169

6.  Large-Scale Chemical-Genetic Strategy Enables the Design of Antimicrobial Combination Chemotherapy in Mycobacteria.

Authors:  Eachan O Johnson; Emma Office; Tomohiko Kawate; Marek Orzechowski; Deborah T Hung
Journal:  ACS Infect Dis       Date:  2019-11-28       Impact factor: 5.084

Review 7.  What is synergy? The Saariselkä agreement revisited.

Authors:  Jing Tang; Krister Wennerberg; Tero Aittokallio
Journal:  Front Pharmacol       Date:  2015-09-01       Impact factor: 5.810

8.  Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis.

Authors:  Murat Cokol; Nurdan Kuru; Ece Bicak; Jonah Larkins-Ford; Bree B Aldridge
Journal:  Sci Adv       Date:  2017-10-11       Impact factor: 14.136

9.  SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Authors:  Aleksandr Ianevski; Liye He; Tero Aittokallio; Jing Tang
Journal:  Bioinformatics       Date:  2017-08-01       Impact factor: 6.937

10.  Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy.

Authors:  Natacha Comandante-Lou; Mehwish Khaliq; Divya Venkat; Mohan Manikkam; Mohammad Fallahi-Sichani
Journal:  PLoS Comput Biol       Date:  2020-02-21       Impact factor: 4.475

View more
  18 in total

1.  Comparative analysis of molecular fingerprints in prediction of drug combination effects.

Authors:  B Zagidullin; Z Wang; Y Guan; E Pitkänen; J Tang
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

2.  Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry.

Authors:  Xiyuan Lu; G Lavender Hackman; Achinto Saha; Atul Singh Rathore; Meghan Collins; Chelsea Friedman; S Stephen Yi; Fumio Matsuda; John DiGiovanni; Alessia Lodi; Stefano Tiziani
Journal:  iScience       Date:  2022-04-07

3.  ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells.

Authors:  Peter Cruz-Gordillo; Megan E Honeywell; Nicholas W Harper; Thomas Leete; Michael J Lee
Journal:  Sci Signal       Date:  2020-11-17       Impact factor: 8.192

Review 4.  Drug combination therapy for emerging viral diseases.

Authors:  Zeenat A Shyr; Yu-Shan Cheng; Donald C Lo; Wei Zheng
Journal:  Drug Discov Today       Date:  2021-05-21       Impact factor: 7.851

Review 5.  Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.

Authors:  Adrian J Green; Benedict Anchang; Farida S Akhtari; David M Reif; Alison Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2021-05-28       Impact factor: 2.638

6.  Inhibitor Combinations Reveal Wiring of the Proteostasis Network in Prostate Cancer Cells.

Authors:  Arielle Shkedi; Michael Adkisson; Andrew Schroeder; Walter L Eckalbar; Szu-Yu Kuo; Leonard Neckers; Jason E Gestwicki
Journal:  J Med Chem       Date:  2021-10-04       Impact factor: 8.039

7.  COMBSecretomics: A pragmatic methodological framework for higher-order drug combination analysis using secretomics.

Authors:  Efthymia Chantzi; Michael Neidlin; George A Macheras; Leonidas G Alexopoulos; Mats G Gustafsson
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

8.  Transcriptomics predicts compound synergy in drug and natural product treated glioblastoma cells.

Authors:  Lavinia-Lorena Pruteanu; Liliya Kopanitsa; Dezső Módos; Edgars Kletnieks; Elena Samarova; Andreas Bender; Leonardo Dario Gomez; David Stanley Bailey
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

9.  Drug synergy scoring using minimal dose response matrices.

Authors:  Petri Mäkelä; Si Min Zhang; Sean G Rudd
Journal:  BMC Res Notes       Date:  2021-01-19

Review 10.  Predicting and Quantifying Antagonistic Effects of Natural Compounds Given with Chemotherapeutic Agents: Applications for High-Throughput Screening.

Authors:  G Lavender Hackman; Meghan Collins; Xiyuan Lu; Alessia Lodi; John DiGiovanni; Stefano Tiziani
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.